Clinical trial
A Phase 3 Study to Evaluate the Glucose Response of G-Pen (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes
NCT03091673 is registered in ClinicalTrials.gov with Xeris Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study to Evaluate the Glucose Response of G-Pen (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes
- Lead sponsor
- Xeris Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 27, 2017
- Completion date
- September 27, 2017
- Enrollment
- 31 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.